• A new AI-enabled breast-cancer testing opportunity in the UK has put EDX Medical firmly in focus, alongside the company’s investor presentation and broader diagnostic portfolio.
• Attention remains on Fusion Antibodies’ laboratory services and drug-development capabilities, with investors watching contract wins, customer activity and progress across its scientific pipeline.
• hVIVO remains in focus around human-challenge trials, clinical-services demand, customer wins and the conversion of its specialist research platform into recurring revenue.
• The market is watching ImmuPharma’s clinical and partnering pipeline, funding runway and progress toward meaningful development milestones across its specialist drug programmes.
• Renalytix is in focus after major commercial progress with its U.S. distribution strategy, with investors watching the planned 2027 launch, testing volumes and cash runway.
The immediate reason the stock is attracting attention is clear. Cambridge Cognition is in focus as investors assess its neuroscience technology platform and the commercial progress shown in its 2026 interim results. First-halfRevenueincreased 16% to £5.0 million and contracted orders supported a full-year revenue …
The immediate reason the stock is attracting attention is clear. Poolbeg is in focus around its clinical pipeline, its POLB 001 programme, its oral GLP-1 programme and the company's partnering-led model. Recent investor materials continue to emphasize a cash runway into Q2 2028 and …
Key Highlights• Smith & Nephew is in focus on 11 November 2026 after the company confirmed that its second and final buybackTrancheis commencing, with an aggregate programme value of up to US$250 million and a maximum of 68.25 million ordinary shares under the remaining …
Key Highlights• ECO Animal Health is in focus on 11 November 2026 after the company submitted an application and supporting dossier to the European Medicines Agency for its live poultryVaccinetargeting Mycoplasma gallisepticum.• Investors are watching the next milestone, financial implications and execution for LSE:EAH.Why …
Key Highlights• ECO Animal Health is in focus on 11 November 2026 after the company is using its investor-focused update to outline progress across its animal-health portfolio, including itsVaccinepipeline and commercial priorities.• Investors are watching the next milestone, financial implications and execution for LSE:EAH.Why …